Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Entacingene turiparvovec - MeiraGTx

Next Previous
Drug Profile

Entacingene turiparvovec - MeiraGTx

Alternative Names: A-002 - MeiraGTx; AAV-CNGB3; AAV2/8-hCARp.hCNGB3; Adenovirus associated viral vector serotype 8 containing the human CNGB3 gene - MeiraGTx

Latest Information Update: 10 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCL Business
  • Developer MeiraGTx
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action CNBG3 gene expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Colour vision defects
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Colour vision defects

Most Recent Events

  • 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
  • 10 Nov 2021 MeiraGTx in collaboration with Janssen plans clinical trial for Colour vision defects, in 2022
  • 30 Nov 2020 Entacingene turiparvovec is still in phase I/II trial for Colour vision defects in United Kingdom (MeiraGTx pipeline, November 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top